Lori Anne Kunkel - 08 Dec 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Reporting relationship: Director
Issuer ticker: ORIC
Reported as of: 08 Dec 2025
Net transaction value: +$79,000
SEC form: 4
Accepted by SEC: 09 Dec 2025, 17:35:02 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Christian Kuhlen, attorney-in-fact

Key filing fact

Lori Anne Kunkel filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 09 Dec 2025.

Key facts

This page summarizes Lori Anne Kunkel's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Dec 2025, 17:35.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: +$79,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001536368 Primary reporting owner

Kunkel Lori Anne

Relationship: Director
Address: C/O ORIC PHARMACEUTICALS, INC., 240 EAST GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Christian Kuhlen, attorney-in-fact
Signature date: 09 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORIC transaction

Common Stock

Options Exercise

Transaction value: $79,000
Shares: +10,000
Change %: +13%
Price: $7.90
Shares after: 84,200
Date: 08 Dec 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORIC transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -10,000
Change %: -39%
Price: $0.000000
Shares after: 15,600
Date: 08 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $7.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant.